Amphastar Pharmaceuticals, Inc. 8-K

What Happened
Amphastar Pharmaceuticals (through its Chinese subsidiary Amphastar Nanjing Pharmaceuticals, Inc.) announced two agreements dated March 3, 2026: a Supply Agreement with Nanjing Letop Biotechnology Co., Ltd. for manufacture and delivery of chemical intermediates, and an amendment to its Contract Research Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. The Supply Agreement runs for five years, requires no minimum purchase obligations, and payments will be made in Chinese yuan. The Contract Research Amendment shifts use of research cell banks to produce Master Cell Banks for product candidate AMP‑105 (instead of AMP‑107) and increases the total contract cost by approximately $0.6 million. Both transactions are related‑party arrangements (family members of Amphastar’s executives have ownership roles in Letop and Hanxin) and were reviewed and approved by the company’s Audit Committee.

Key Details

• Agreements effective March 3, 2026.
• Supply Agreement term: 5 years; ANP has no minimum purchase obligation; payments in Chinese yuan.
• Contract Research Amendment increases contract cost by about $0.6 million and changes work from AMP‑107 to AMP‑105.
• Both transactions involve related parties (Henry Zhang has majority ownership in Letop; family members and management ties to Hanxin); Audit Committee evaluated and approved the transactions.

Why It Matters
These agreements secure a potential supplier for chemical intermediates and adjust research work for a clinical candidate, but Amphastar states neither transaction is material to its financial condition or results of operations. The related‑party nature and Audit Committee approval are important governance disclosures for investors to note. The amendment also implies a modest near‑term increase in research spend (~$0.6M). As with all forward‑looking items, Amphastar cautions results depend on future performance and risks described in its SEC filings.